Dental impact of anti-fibroblast growth factor 23 therapy in X-linked hypophosphatemia

Dental impact of anti-fibroblast growth factor 23 therapy in X-linked hypophosphatemia

Abstract Elevated fibroblast growth factor 23 (FGF23) in X-linked hypophosphatemia (XLH) results in rickets and phosphate wasting, manifesting by severe bone and dental abnormalities. Burosumab, a FGF23-neutralizing antibody, an alternative to conventional treatment (phosphorus and active vitamin D...

Full description

Bibliographic Details
Main Authors: Elis J. Lira dos Santos, Kenta Nakajima, Julien Po, Ayako Hanai, Volha Zhukouskaya, Martin Biosse Duplan, Agnès Linglart, Takashi Shimada, Catherine Chaussain, Claire Bardet
Format: Article
Language:English
Published: Nature Publishing Group 2023-12-01
Series:International Journal of Oral Science
Online Access:https://doi.org/10.1038/s41368-023-00259-8

Internet

https://doi.org/10.1038/s41368-023-00259-8

Similar Items